CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details
Nur Naqvi
Chief Technology Officer Profile

Similar Companies

BNC National Bank

BNCCORP, Inc. (OTCQB: BNCC), headquartered in Bismarck, N.D., is a registered bank holding company dedicated to providing banking and wealth management services to businesses and consumers in its local markets. The Company operates community banking and wealth management businesses in Arizona, Minnesota and North Dakota. BNC also conducts mortgage banking from locations in the Midwest. The Company offers financial products and services to meet the financial needs of its current customers, and potential customers, in the markets it serves.

Unified Door & Hardware Group

Unified Door & Hardware Group is a prominent distributor and service provider of commercial doors, hardware, and building specialties, located in Pennsauken, New Jersey. Established in 2013 from the merger of Commercial Hardware and TruFit, the company operates 31 locations nationwide and employs around 1,000 people, generating $92 million in revenue. In September 2024, it was acquired by Foundation Building Materials. The company offers a wide range of products and services across various construction divisions. This includes commercial doors and hardware, building specialties like bathroom partitions and fire protection, and access control systems. Unified Door & Hardware Group also provides custom fabrication, project management, professional engineering services, and installation for both new construction and aftermarket projects. They cater to diverse sectors such as healthcare, hospitality, government, and retail, working closely with contractors, developers, and building owners. Their extensive industry experience and commitment to personalized service set them apart in the market.

XLI Manufacturing, LLC

XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.

STARK

STARK Group is a leading provider of building materials and services for the construction industry in Europe. Founded in 1896 and headquartered in Frederiksberg, Denmark, the company operates over 1,100 branches and distribution centers across Europe, employing around 19,000 people. STARK Group specializes in the distribution and retail of building materials to professional builders and contractors. They offer product knowledge and advice to help customers select the right materials for their projects. The company also provides efficient logistics solutions to ensure timely delivery of products to construction sites. Their extensive product portfolio includes a wide range of heavy construction materials tailored to meet the diverse needs of the construction sector. STARK Group is committed to sustainability, investing in environmentally friendly facilities and aiming for low-emission classifications in their operations.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.